{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T02:10:26Z","timestamp":1782526226911,"version":"3.54.5"},"reference-count":26,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"unspecified","delay-in-days":259,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Pall Supp Care"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S1478951525100722_sec1a\">\n\t    <jats:title>Objectives<\/jats:title>\n\t    <jats:p>Duloxetine is the only agent for chemotherapy-induced peripheral neuropathy (CIPN) recommended by the American Society of Clinical Oncology. As a moderate inhibitor of cytochrome P450 isoenzyme 2D6, duloxetine is theorized to decrease the efficacy of tamoxifen, which may be used to treat estrogen receptor\u2013positive breast cancer. A case prompted our team to review the literature to elucidate the risks and benefits of duloxetine use in patients with this cancer.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S1478951525100722_sec2b\">\n\t    <jats:title>Methods<\/jats:title>\n\t    <jats:p>We present the case of a patient with estrogen receptor\u2013positive breast cancer who was doing well on duloxetine for CIPN. Due to concern for the possible future need for tamoxifen, she was switched to multiple other agents, including venlafaxine, without success.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S1478951525100722_sec3c\">\n\t    <jats:title>Results<\/jats:title>\n\t    <jats:p>Ultimately, the patient was switched back to duloxetine due to persistent CIPN symptoms. The theoretical risk of tamoxifen interaction with duloxetine has not been demonstrated to be clinically significant in the literature.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S1478951525100722_sec4d\">\n\t    <jats:title>Significance of results<\/jats:title>\n\t    <jats:p>While emerging evidence suggests venlafaxine may prove an effective alternative, duloxetine remains the agent with the strongest evidence of benefit in patients with CIPN and must remain an option in this patient population.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/s1478951525100722","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T09:12:56Z","timestamp":1758100376000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":3,"title":["Benefits of duloxetine may outweigh risks in a patient with hormone-positive breast cancer"],"prefix":"10.1017","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6619-866X","authenticated-orcid":false,"given":"Gustavo Scannapieco","family":"Mastroleo","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3059-3083","authenticated-orcid":false,"given":"Kayley","family":"Ancy","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7628-8675","authenticated-orcid":false,"given":"Akhila","family":"Reddy","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"S1478951525100722_ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-3009-x"},{"key":"S1478951525100722_ref6","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.clbc.2022.12.018","article-title":"Letter to the Editor of Clinical Breast Cancer, on \u201cTime to Update Evidence-Based Guideline Recommendations About Concurrent Tamoxifen and Antidepressant Use? A Systematic Review,\u201d Conducted by Michelle Bradbury and Collaborators and Published in Clinical Breast Cancer April Vol 22 no.4 e362-e373, 2022","volume":"23","author":"de Oliveira","year":"2023","journal-title":"Clinical Breast Cancer"},{"key":"S1478951525100722_ref20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23008"},{"key":"S1478951525100722_ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01399"},{"key":"S1478951525100722_ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2813"},{"key":"S1478951525100722_ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1080888"},{"key":"S1478951525100722_ref19","doi-asserted-by":"publisher","DOI":"10.55729\/2000-9666.1289"},{"key":"S1478951525100722_ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076648"},{"key":"S1478951525100722_ref22","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg108"},{"key":"S1478951525100722_ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01535"},{"key":"S1478951525100722_ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv337"},{"key":"S1478951525100722_ref26","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"S1478951525100722_ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3664-y"},{"key":"S1478951525100722_ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.24140"},{"key":"S1478951525100722_ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002396"},{"key":"S1478951525100722_ref7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdr045","article-title":"Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial","volume":"23","author":"Durand","year":"2012","journal-title":"Annals of Oncology"},{"key":"S1478951525100722_ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1162-y"},{"key":"S1478951525100722_ref9","article-title":"Venlafaxine for neuropathic pain in adults","volume":"2015","author":"Gallagher","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"S1478951525100722_ref14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c693","article-title":"Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study","volume":"340","author":"Kelly","year":"2010","journal-title":"Bmj (British Medical Journal)"},{"key":"S1478951525100722_ref23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.19.01412","article-title":"CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): a Randomized, Open-Label, Phase II Study","volume":"38","author":"Tamura","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"S1478951525100722_ref24","doi-asserted-by":"publisher","DOI":"10.1053\/eujp.2001.0266"},{"key":"S1478951525100722_ref3","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12484"},{"key":"S1478951525100722_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2021.10.003"},{"key":"S1478951525100722_ref18","unstructured":"National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer (Version 4.2024) https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed October 15, 2024 ."},{"key":"S1478951525100722_ref1","first-page":"1999","article-title":"Treatment of neuropathic pain with venlafaxine: A systematic review","volume":"18","author":"Aiyer","year":"2017","journal-title":"Pain Medicine"},{"key":"S1478951525100722_ref13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2017.74.6651","article-title":"Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202","volume":"36","author":"Henry","year":"2018","journal-title":"Journal of Clinical Oncology"}],"container-title":["Palliative and Supportive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1478951525100722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T09:13:00Z","timestamp":1758100380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1478951525100722\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":26,"alternative-id":["S1478951525100722"],"URL":"https:\/\/doi.org\/10.1017\/s1478951525100722","relation":{},"ISSN":["1478-9515","1478-9523"],"issn-type":[{"value":"1478-9515","type":"print"},{"value":"1478-9523","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"\u00a9 The Author(s), 2025. Published by Cambridge University Press.","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0), which permits non-commercial re-use, distribution, and reproduction in any medium, provided that no alterations are made and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use and\/or adaptation of the article.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e172"}}